Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-02-06 Purchase | 2026-02-09 9:19 pm | Eikon Therapeutics Inc. | EIKN | Column Group IV GP LP Column Group IV-A LP Column Group IV LP Column Group Opportunity III LP Column Group Opportunity III GP LP TCG Opportunity III GP LLC Kutzkey Tim Svennilson Peter 10% Owner | 2,117,760 | $18 | $38,119,680 | 1,319,164 (Indirect) | View |
| 2026-02-04 Purchase | 2026-02-06 7:37 pm | Eikon Therapeutics Inc. | EIKN | Foresite Capital Management IV LLC Foresite Capital Fund IV L.P. Foresite Capital Management V LLC Foresite Capital Fund V L.P. Foresite Capital Opportunity Management V LLC Foresite Capital Opportunity Fund V L.P. Foresite Capital VI-A Management LLC Foresite Capital VI-A LLC 10% Owner | 55,555 | $18 | $999,990 | 1,370,260 (Indirect) | View |
| 2026-02-04 Purchase | 2026-02-06 6:33 pm | Eikon Therapeutics Inc. | EIKN | FRAZIER KENNETH C Director | 111,111 | $18 | $1,999,998 | 111,111 (Direct) | View |
| 2026-02-04 Purchase | 2026-02-06 6:27 pm | Eikon Therapeutics Inc. | EIKN | Wolfe Josh Director 10% Owner | 277,776 | $18 | $4,999,968 | 2,294,653 (Indirect) | View |
| 2026-02-04 Purchase | 2026-02-06 6:25 pm | Eikon Therapeutics Inc. | EIKN | Lux Venture Partners V LLC Wolfe Josh Hebert Peter Lux Ventures V L.P. Lux Co-Invest Opportunities II L.P. Lux Total Opportunities L.P. 10% Owner | 277,776 | $18 | $4,999,968 | 2,294,653 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-03-02 Option Award | 2026-03-04 5:04 pm | N/A 2036-03-01 | Eikon Therapeutics Inc. | EIKN | Klobuchar Michael A Chief Operating Officer | 87,157 | $0 | 87,157 (Direct) | View |
| 2026-03-02 Option Award | 2026-03-04 5:02 pm | N/A 2036-03-01 | Eikon Therapeutics Inc. | EIKN | Huffines Robert Luther Director | 25,873 | $0 | 25,873 (Direct) | View |
| 2026-03-02 Option Award | 2026-03-04 5:01 pm | N/A 2036-03-01 | Eikon Therapeutics Inc. | EIKN | FRAZIER KENNETH C Director | 25,873 | $0 | 25,873 (Direct) | View |
| 2026-03-02 Option Award | 2026-03-04 5:00 pm | N/A 2036-03-01 | Eikon Therapeutics Inc. | EIKN | PERLMUTTER ROGER M See remarks | 268,176 | $0 | 268,176 (Direct) | View |
| 2026-03-02 Option Award | 2026-03-04 4:59 pm | N/A 2036-03-01 | Eikon Therapeutics Inc. | EIKN | Thorner Benjamin Bruno See Remarks | 67,044 | $0 | 67,044 (Direct) | View |
| 2026-03-02 Option Award | 2026-03-04 4:59 pm | N/A 2036-03-01 | Eikon Therapeutics Inc. | EIKN | Baynes Roy D. Chief Medical Officer | 134,088 | $0 | 134,088 (Direct) | View |
| 2026-03-02 Option Award | 2026-03-04 4:58 pm | N/A 2036-03-01 | Eikon Therapeutics Inc. | EIKN | Bowie Alfred Lloyd Jr. Chief Financial Officer | 67,044 | $0 | 67,044 (Direct) | View |
| 2026-02-06 Conversion | 2026-02-10 5:06 pm | N/A N/A | Eikon Therapeutics Inc. | EIKN | PERLMUTTER ROGER M See remarks | 2,409,260 | $0 | 284,857 (Indirect) | View |
| 2026-02-06 Conversion | 2026-02-09 9:19 pm | N/A N/A | Eikon Therapeutics Inc. | EIKN | Column Group IV GP LP Column Group IV-A LP Column Group IV LP Column Group Opportunity III LP Column Group Opportunity III GP LP TCG Opportunity III GP LLC Kutzkey Tim Svennilson Peter 10% Owner | 30,408,665 | $0 | 1,319,164 (Indirect) | View |
| 2026-02-04 Conversion | 2026-02-06 7:37 pm | N/A N/A | Eikon Therapeutics Inc. | EIKN | Foresite Capital Management IV LLC Foresite Capital Fund IV L.P. Foresite Capital Management V LLC Foresite Capital Fund V L.P. Foresite Capital Opportunity Management V LLC Foresite Capital Opportunity Fund V L.P. Foresite Capital VI-A Management LLC Foresite Capital VI-A LLC 10% Owner | 34,108,086 | $0 | 1,370,260 (Indirect) | View |
| 2026-02-06 Conversion | 2026-02-06 6:27 pm | N/A N/A | Eikon Therapeutics Inc. | EIKN | Wolfe Josh Director 10% Owner | 48,167,251 | $0 | 2,294,653 (Indirect) | View |
| 2026-02-06 Conversion | 2026-02-06 6:25 pm | N/A N/A | Eikon Therapeutics Inc. | EIKN | Lux Venture Partners V LLC Wolfe Josh Hebert Peter Lux Ventures V L.P. Lux Co-Invest Opportunities II L.P. Lux Total Opportunities L.P. 10% Owner | 48,167,251 | $0 | 2,294,653 (Indirect) | View |
Ownership | 2026-02-04 9:59 pm | N/A N/A | Eikon Therapeutics Inc. | EIKN | Column Group IV GP LP Column Group IV-A LP Column Group Opportunity III LP Column Group Opportunity III GP LP TCG Opportunity III GP LLC 10% Owner | 0 | $0 | 4,235,952 (Indirect) | View |
Ownership | 2026-02-04 9:35 pm | N/A N/A | Eikon Therapeutics Inc. | EIKN | Foresite Capital Management IV LLC Foresite Capital Fund IV L.P. Foresite Capital Fund V L.P. Foresite Capital Management V LLC Foresite Capital Opportunity Fund V L.P. Foresite Capital Opportunity Management V LLC Foresite Capital VI-A LLC Foresite Capital VI-A Management LLC 10% Owner | 0 | $0 | 4,092,964 (Indirect) | View |
Ownership | 2026-02-04 9:34 pm | N/A N/A | Eikon Therapeutics Inc. | EIKN | Bowie Alfred Lloyd Jr. Chief Financial Officer | 0 | $0 | 230,629 (Direct) | View |
Ownership | 2026-02-04 9:32 pm | N/A 2033-11-16 | Eikon Therapeutics Inc. | EIKN | Huffines Robert Luther Director | 0 | $0 | 67,043 (Direct) | View |
Ownership | 2026-02-04 9:30 pm | N/A N/A | Eikon Therapeutics Inc. | EIKN | Wolfe Josh Director 10% Owner | 0 | $0 | 5,695,010 (Indirect) | View |
Ownership | 2026-02-04 9:24 pm | N/A 2035-11-20 | Eikon Therapeutics Inc. | EIKN | Meline David W Director | 0 | $0 | 67,043 (Direct) | View |
Ownership | 2026-02-04 9:22 pm | N/A 2032-05-30 | Eikon Therapeutics Inc. | EIKN | Baynes Roy D. Chief Medical Officer | 0 | $0 | 268,174 (Direct) | View |
Ownership | 2026-02-04 9:21 pm | N/A 2032-08-07 | Eikon Therapeutics Inc. | EIKN | FRAZIER KENNETH C Director | 0 | $0 | 83,803 (Direct) | View |
Ownership | 2026-02-04 9:21 pm | N/A N/A | Eikon Therapeutics Inc. | EIKN | PERLMUTTER ROGER M See remarks | 0 | $0 | 3,954,318 (Direct) | View |
Ownership | 2026-02-04 9:19 pm | N/A 2035-05-02 | Eikon Therapeutics Inc. | EIKN | Klobuchar Michael A Chief Operating Officer | 0 | $0 | 174,313 (Direct) | View |
Ownership | 2026-02-04 9:18 pm | N/A 2032-01-20 | Eikon Therapeutics Inc. | EIKN | Thorner Benjamin Bruno See remarks | 0 | $0 | 268,173 (Direct) | View |
Ownership | 2026-02-04 9:11 pm | N/A N/A | Eikon Therapeutics Inc. | EIKN | Lux Venture Partners V LLC Wolfe Josh Hebert Peter Lux Ventures V L.P. Lux Co-Invest Opportunities II L.P. Lux Total Opportunities L.P. 10% Owner | 0 | $0 | 5,695,010 (Indirect) | View |